PALATIN TECHNOLOGIES INC (PTN)
US6960775020 - Common Stock
PTN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. PTN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PTN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PTN has reported negative net income.
PTN had a negative operating cash flow in the past year.
PTN had negative earnings in 4 of the past 5 years.
PTN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -233.08%, PTN is doing worse than 90.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-101.35%
ROA(5y)-59.25%
ROE(3y)-9276.56%
ROE(5y)-5564.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTN has a Gross Margin of 95.39%. This is amongst the best in the industry. PTN outperforms 96.75% of its industry peers.
PTN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTN has more shares outstanding
PTN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PTN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -50.13, we must say that PTN is in the distress zone and has some risk of bankruptcy.
PTN has a Altman-Z score of -50.13. This is amonst the worse of the industry: PTN underperforms 93.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -50.13 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
PTN has a Current Ratio of 1.09. This is a normal value and indicates that PTN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.09, PTN is not doing good in the industry: 87.16% of the companies in the same industry are doing better.
PTN has a Quick Ratio of 1.09. This is a normal value and indicates that PTN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.09, PTN is doing worse than 86.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
PTN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.23%, which is quite good.
Looking at the last year, PTN shows a very strong growth in Revenue. The Revenue has grown by 145.82%.
Measured over the past years, PTN shows a very negative growth in Revenue. The Revenue has been decreasing by -40.88% on average per year.
EPS 1Y (TTM)16.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-330.77%
Revenue 1Y (TTM)145.82%
Revenue growth 3Y243.18%
Revenue growth 5Y-40.88%
Revenue growth Q2Q97.49%
3.2 Future
The Earnings Per Share is expected to grow by 13.89% on average over the next years. This is quite good.
The Revenue is expected to grow by 46.27% on average over the next years. This is a very strong growth
EPS Next Y15.1%
EPS Next 2Y27.15%
EPS Next 3Y30.4%
EPS Next 5Y13.89%
Revenue Next Year-3.81%
Revenue Next 2Y29.42%
Revenue Next 3Y112.86%
Revenue Next 5Y46.27%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PTN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PTN's earnings are expected to grow with 30.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.15%
EPS Next 3Y30.4%
5. Dividend
5.1 Amount
PTN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PALATIN TECHNOLOGIES INC
NYSEARCA:PTN (4/23/2024, 7:20:53 PM)
After market: 1.79 +0.04 (+2.29%)1.75
+0.03 (+1.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap28.25M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.08% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.39% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.23%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)145.82%
Revenue growth 3Y243.18%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y